NASDAQ false 0001598646 0001598646 2026-11-12 2026-11-12
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 12, 2026

 

 

Minerva Neurosciences, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   000-36517   26-0784194
(State or other jurisdiction
of incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)

1500 District Avenue, Burlington, MA 01803

(Address of principal executive offices) (Zip Code)

(617) 600-7373

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange
on which registered

Common Stock, $0.0001 par value per share   NERV   The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 


Item 7.01.

Regulation FD Disclosure.

On November 12, 2026, Minerva Neurosciences, Inc. (the “Company”) hosted a key opinion leader event regarding roluperidone, the Company’s product candidate for the treatment of negative symptoms in patients diagnosed with schizophrenia (the “KOL Event”).

Frank Sasinowski, the Company’s regulatory counsel, participated in the discussion based on his experience and involvement in the Company’s discussions with the U.S. Food and Drug Administration (the “FDA”). During the KOL Event, he expressed his personal views concerning the potential regulatory outcome in the event the Company receives positive results from the initial 12-week, placebo-controlled portion of the Company’s ongoing C19 Phase 3 clinical trial (“Phase A”), and he characterized his view of certain FDA discussions and clinical findings.

The Company is furnishing a revised transcript of the KOL Event as Exhibit 99.1 to this Current Report on Form 8-K in order to clarify certain statements made during the KOL Event. Mr. Sasinowski’s expressions of confidence regarding potential approval reflected his personal opinions and predictions and should not be understood as assurances regarding any future action or decision by the FDA. Any decision by the Company to resubmit its New Drug Application (“NDA”) for roluperidone will depend on the results of the C19 trial, the complete data package and further assessment. Positive results from Phase A, if obtained, would not, by themselves, assure approval of a resubmitted NDA. The FDA has not committed to approval of roluperidone, and the acceptability of any resubmission and the ultimate regulatory outcome including the specific language of any approved labeling would remain subject to the FDA’s review of the complete submission.

The Company remains committed to completing the relapse comparison portion of the C19 trial (“Phase B”). The Company maintains ongoing discussions with the FDA and plans to review the Phase A results with the FDA when topline results are available.

In addition, certain statements made during the KOL Event should not be understood as regulatory conclusions of effectiveness or safety for the potential use of roluperidone alone or in combination with any other product, or as indicating that any safety concern identified by the FDA could necessarily be resolved through product labeling. References during the KOL Event to personal relationships and escalation were intended to describe potential opportunities for additional communication with the FDA and should not be understood as suggesting preferential treatment or access or providing any assurance of a favorable regulatory decision.

To address these matters, the question-and-answer session at the end of the KOL Event, during which the statements concerning approval predictions, safety and professional relationships were made, has been removed from the revised transcript furnished as Exhibit 99.1. Investors should not rely on the statements that have been removed. The revised transcript supersedes any previously published transcript of the KOL Event.

The information in this Item 7.01 of this Current Report on Form 8-K, including the accompanying Exhibit 99.1, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

 

 

2


Item 8.01.

Other Events.

The Company is filing an updated investor presentation as Exhibit 99.2 to this Current Report on Form 8-K, which the Company may use from time to time in conversations with investors and analysts.

 

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit

Number

  

Description

99.1    Revised transcript of Minerva Neurosciences, Inc. Key Opinion Leader Event held on November 12, 2026.
99.2    Corporate Presentation
104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

3


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: November 16, 2026     MINERVA NEUROSCIENCES, INC.
     

/s/ Fred Ahlholm

      Name: Fred Ahlholm
      Title: Chief Financial Officer

 

4